Molecular Insight Pharmaceuticals cuts jobs to focus on R&D

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Molecular Insight Pharmaceuticals (MIP) has eliminated nine positions in alignment with its plan to support the development of its oncology product candidates and to reduce operating costs.

The Cambridge, Mass.-based MIP now has 61 employees and five clinical-stage oncology products--two of which the company expects to begin Phase III confirmatory trials in 2010.

After a one-time charge of approximately $200,000 in the first quarter of 2010, MIP said it expects to achieve approximately $1 million in annualized savings in its operating expenses as a result of the reduction.